Recent studies have reported beneficial hepatic effects of PPARγ agonists in reversing nonalcoholic steatohepatitis (NASH) in patients, reducing liver inflammation, fibrosis and triglyceride content [128,129]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatohepatitis.